Skip to main content

Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data

There is likely a long way to go before the U.S. sees increased insurance coverage of obesity drugs, but Novo Nordisk's new data is a meaningful start.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.